Rachelle Doody
| Rachelle Doody | |
|---|---|
| Born | |
| 🎓 Alma mater | Rice University |
| 💼 Occupation | |
| Twitter= | |
Script error: No such module "Draft topics". Script error: No such module "AfC topic".
Rachelle Smith Doody is an American neurologist and Neuroscientist. Since 2016 she is the Vice President, Global Head of Neurodegeneration and the Alzheimer's Disease and Neurodegeneration Franchise Head in Product Development, Neuroscience at Roche Pharmaceutical Company and it US entity, Genentech. She oversees late stage development of drugs for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative disorders.[1]
Profile in the Lancet[2]
Education and career[edit]
Doody holds a B.A. in English in 1978 and M.A./Ph.D. in Cognitive Anthropology in 1992 from Rice University.[3] She did her medical training at Baylor College of Medicine in Houston, Texas, obtaining her M.D. in 1983. After medical school, Doody took a year of internship in internal medicine at McGill University in Montreal, Canada and then back to the Baylor College of Medicine in Houston she did a residency in Neurology, finishing in 1987.
Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas.[4]
where she had founded and directed the Alzheimer’s Disease and Memory Disorders Center and where she is now Distinguished Professor Emeritus.
In 2016 she moved to Genentech/Roche.
Her fieldwork experiences include studying cognition among non-literate Karen hill tribes in Northern Thailand.
'alien hand syndrome' in the paper[5]
Doody was the Principle Investigator for the Phase 2 and 3 development of donepezil (Aricept), and worked with numerous biotech and pharma companies over a period of 25 years in the design and execution of treatment trials for cognitive and behavioral treatment of AD. She has contributed to efforts to globalize the diagnosis and treatment of AD, including advising on guidelines in China, Malaysia, South Korea and the Philippines, educating investigators throughout Europe and Asia on study design issues, and training investigators on outcome measures to support global studies.
Selected publications[edit]
Doody has published over 200 original research articles primarily dealing with the diagnosis and treatment of Alzheimer’s disease and related neurodegenerative disorders[6][7]
Awards and honors[edit]
Doody received a Distinguished Alumni Award from Rice University in 2009[3] and a Distinguished Faculty Award from Baylor College of Medicine in 2011.
In 2018 she received a Lifetime Achievement Award from the Clinical Trials in Alzheimer’s Disease Society.[7][better source needed]
References[edit]
- ↑ "Rachelle Doody Biography". thelancetsummit.com.
- ↑ Williams, Ruth (2011). "Rachelle Doody: an appetite for variety". The Lancet Neurology. 10 (1): 28. doi:10.1016/s1474-4422(10)70317-3. ISSN 1474-4422. PMID 21163443. Unknown parameter
|s2cid=ignored (help) - ↑ 3.0 3.1 "Past Laureates Honorees". The Association of Rice Alumni | Rice University. Retrieved 2022-09-29.
- ↑ "Rachelle Doody". Baylor College of Medicine. Retrieved 2022-09-29.
- ↑ Mough, Thomas H. (1991-04-25). "Researchers attempt to pinpoint 'alien hand syndrome'". The Los Angeles Times. p. 372. Retrieved 2022-09-29.
- ↑ "Rachelle Doody Biography". bcm.edu.
- ↑ 7.0 7.1 "Rachelle Doody Biography". horizons.health.
This article "Rachelle S.Doody" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Rachelle S.Doody. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
